A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus.
Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ.
PLoS Pathog. 2011 Feb;7(2):e1001294. Epub 2011 Feb 17.

The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.
Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.
J Virol. 2011 Feb;85(4):1604-14. Epub 2010 Dec 1.

Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.
Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A.
J Virol. 2010 Apr;84(7):3612-23. Epub 2010 Jan 20.

Epstein-Barr virus genetics: talking about the BAC generation.
Feederle R, Bartlett EJ, Delecluse HJ.
Herpesviridae. 2010 Dec 7;1(1):6.

Busse C, Feederle R, Schnölzer M, Behrends U, Mautner J, Delecluse HJ.
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
J Virol. 2010, 8:1139-47.

Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, Zavolan M, Polacek N, Delecluse HJ, Hüttenhofer A.
Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome.
PLoS Pathog. 2009, 5:e1000547.

Feederle R, Bannert H, Lips H, Müller-Lantzsch N, Delecluse HJ.
The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication.
J Virol. 2009, 83:4952-62.

Neuhierl B, Feederle R, Adhikary D, Hub B, Geletneky K, Mautner J, Delecluse HJ.
Primary B cell infection with a ΔBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T cell response.
J Virol. 2009, 83: 4616-23.

Delecluse HJ, Feederle R, Behrends U, Mautner J.
Contributions of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Semin Cancer Biol. 2008, 18: 409-415.

Granato M, Feederle R, Farina A, Gonnella R, Santarelli R, Hub B, Faggioni A, Delecluse HJ.
Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles.
J Virol. 2008, 82:4042-51.

Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J.
Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
J Virol. 2008, 82: 3903-11

Feederle R, Neuhierl B, Bannert H, Geletneky K, Shannon-Lowe C, Delecluse HJ.
Epstein-Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals inter-individual variation susceptibility to viral infection.
Int. J. Cancer. 2007, 121: 588-94

Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, Mautner J, Behrends U, Delecluse HJ.
Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes.
J. Virol. 2006, 80: 9435-43

Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ.
Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus.
J Virol. 2005 79: 7641-7

Neuhierl B & Delecluse HJ.
Molecular Genetics of DNA Viruses in "DNA Viruses: Methods and Protocols, 2004".
Methods Mol Biol. 2004; 292: 353-70

Feederle R & Delecluse HJ.
Low level of lytic replication in a recombinant Epstein-Barr virus carrying an origin of replication devoid of BZLF1 binding sites.
J Virol. 2004; 78:12082-4

Bhende PM, Seaman WT, Delecluse HJ, Kenney SC.
The EBV lytic switch protein Z preferentially binds to and activates the methylated viral genome.
Nat Genet, 2004; 36, 1099-1104

Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F, Delecluse HJ.
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma
Lancet, 2003, 361; 217-23

Neuhierl B, Feederle R, Hammerschmidt H & Delecluse HJ.
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.
PNAS, 2002, 99; 15036–15041

HJ Delecluse, M. Kost, W. Hammerschmidt.
An experimental system for the production of infectious particles carrying viral mutants of Kaposi's sarcoma associated virus.
J. Virol. 2001, 75; 2921-2928

Janz, M. Oezel, C. Kurzeder, J. Mautner, D. Pich, M. Kost, W. Hammerschmidt & HJ Delecluse.
An infectious Epstein-Barr virus lacking the major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.
J Virol. 2000, 21; 10142-52

R. Feederle, M. Kost, M. Baumann, A.Janz, E. Drouet, W. Hammerschmidt, & HJ Delecluse.
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.
EMBO J. 2000, 19; 3080-89

HJ Delecluse, D Pich, T Hilsendegen, C Baum & W Hammerschmidt.
A first-generation packaging cell line for Epstein-Barr virus-derived vectors.
PNAS 1999, 96; 5188-93

HJ Delecluse, T Hilsendegen, D Pich, R Zeidler & W Hammerschmidt.
Propagation and recovery of intact, infectious Epstein-Barr Virus from prokaryotic to human cells.
PNAS 1998, 95; 8245-50